Structural variation in the glycogen synthase kinase 3β and brain‐derived neurotrophic factor genes in Japanese patients with bipolar disorders

BACKGROUND: Lithium is the first‐line drug for the treatment of bipolar disorders (BDs); however, not all patients responded. Glycogen synthase kinase (GSK) 3β and brain‐derived neurotrophic factor (BDNF) play a role in the therapeutic action of lithium. Since structural variations were reported in...

Descripción completa

Detalles Bibliográficos
Autores principales: Suga, Yosuke, Yoshimoto, Keiichiro, Numata, Shusuke, Shimodera, Shinji, Takamura, Shogo, Kamimura, Naoto, Sawada, Ken, Kazui, Hiromitsu, Ohmori, Tetsuro, Morinobu, Shigeru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292225/
https://www.ncbi.nlm.nih.gov/pubmed/31769621
http://dx.doi.org/10.1002/npr2.12083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292225/
https://www.ncbi.nlm.nih.gov/pubmed/31769621
http://dx.doi.org/10.1002/npr2.12083

Ejemplares similares